1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2022, Issue 3
  5. Article
Volume 2022, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Background: It remains unclear whether patients with autoimmune rheumatic diseases (ARDs) are at a higher risk of poor outcomes from a SARS-CoV-2 infection. We evaluated whether patients with an ARDs infected with SARS-CoV-2 were at a higher risk of a poorer outcome than those without an ARDs.

Methods: Patients with an ARDs infected with SARS-CoV-2 were matched to control patients without a known ARDs. Matching was performed according to age ( ± 6 years) and sex at a case-to-control ratio of 1:3. Demographic and clinical data were extracted from the databases and were compared between the two groups. Severe SARS-CoV-2 infection was the primary outcome and was defined as the requirement for oxygen therapy support, the need for invasive or noninvasive mechanical ventilation, or the use of glucocorticoids.

Results: A total of 141 patients with an ARDs were matched to 398 patients who formed the control group. The mean ages (SD) of the ARDs and non-ARDs groups were 44.4 years (11.4) and 43.4 years (12.2). Women accounted for 58.8% of the ARDs group and 56.3% of the control group (p = 0.59). Demographics and comorbidities were balanced between the groups. ARDs included connective tissue disease in 43 (30.3%) patients, inflammatory arthritis in 92 (65.2%), and other ARDs in 8 (5.7%). ARDs medications included biological/targeted synthetic disease-modifying antirheumatic drugs (b/ts-DMARDs) in 28 (15.6%) patients, conventional synthetic DMARDs in 95 (67.4%), and immunosuppressive antimetabolites in 13 (9.2%). The ARDs group had more respiratory and gastrointestinal symptoms related to SARS-CoV-2 infection than the control group (24.8% and 20.6% vs. 10% and 5.3%, respectively; p <  0.001 for both). Severe SARS-CoV-2 infection was more common in the ARDs group than in the control group (14.9% vs. 5.8%; p <  0.001).

Conclusions: In this single-center matched cohort study, patients with an ARDs experienced more respiratory and gastrointestinal symptoms related to SARS-CoV-2 infection and had more severe infection than those from the control group. Therefore, patients with an ARDs require close observation during the coronavirus disease 2019 pandemic.

© 2022 Alsaed, Alemadi, Satti, Becetti, Saleh, Ashour, Hamed, Alam, Alrimawi, Nader, Chaponda, Awadh, Hammoudeh, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.24
2022-06-20
2024-11-13
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2022/3/qmj.2022.24.html?itemId=/content/journals/10.5339/qmj.2022.24&mimeType=html&fmt=ahah

References

  1. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953 249:(14):553-6.
     [Google Scholar]
  2. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013 52:(1):53-61.
     [Google Scholar]
  3. Souza DC, Santo AH, Sato EI. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol. 2012 39:(3):496-503.
     [Google Scholar]
  4. Al Kuwari HM, Abdul Rahim HF, Abu-Raddad LJ, Abou-Samra AB, Al Kanaani Z, Al Khal A, et al. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020. BMJ Open. 2020 10:(10):e040428.
     [Google Scholar]
  5. Hanif M, Haider MA, Xi Q, Ali MJ, Ahmed MU. A review of the risk factors associated with poor outcomes in patients with coronavirus disease 2019. Cureus. 2020 12:(9):e10350.
     [Google Scholar]
  6. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19.Meta-analysis. Obes Res Clin Pract. 2020 14:(4):295-300.
     [Google Scholar]
  7. Lokken EM, Huebner EM, Taylor GG, Hendrickson S, Vanderhoeven J, Kachikis A, et al. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet Gynecol. 2021 225:(1):77.e1-14.
     [Google Scholar]
  8. Omrani AS, Almaslamani MA, Daghfal J, Alattar RA, Elgara M, Shaar SH, et al. The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. BMC Infect Dis. 2020 20:(1):777.
     [Google Scholar]
  9. Pranata R, Supriyadi R, Huang I, Permana H, Lim MA, Yonas E, et al. The association between chronic kidney disease and new onset renal replacement therapy on the outcome of COVID-19 patients: a meta-analysis. Clin Med Insights Circ Respir Pulm Med. 2020;:14:1179548420959165.
     [Google Scholar]
  10. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. https://covid19.who.int/?adgroupsurvey. Accessed 21 Sept 2021.
     [Google Scholar]
  11. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 2:(5):e250-3.
     [Google Scholar]
  12. Liew JW, Bhana S, Costello W, Hausmann JS, Machado PM, Robinson PC, et al. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford). 2021 60:(1):353-8.
     [Google Scholar]
  13. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 584:(7821):430-6.
     [Google Scholar]
  14. D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020; 79:(9):1156-62.
     [Google Scholar]
  15. Zhao J, Pang R, Wu J, Guo Y, Yang Y, Zhang L, et al. Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences. Ann Rheum Dis. 2021 80:(5):e63.
     [Google Scholar]
  16. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 80:(7):930-42.
     [Google Scholar]
  17. World Health Organization. Corticosteroids for COVID-19. 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Accessed 21 Sept 2021.
     [Google Scholar]
  18. World Health Organization. Clinical management of COVID-19 - interim guidance 27 May 2020. https://apps.who.int/iris/rest/bitstreams/1278777/retrieve. Accessed 21 Sept 2021.
     [Google Scholar]
  19. Alwahaibi N, Al Maskari M, Al Dhahli B, Al Issaei H, Al-Jaaidi Shadia Al Bahlani S. One-year review of COVID-19 in the Arab world. Qatar Med J. 2021;:(3):66.
     [Google Scholar]
/content/journals/10.5339/qmj.2022.24
Loading
Risk of Severe SARS-CoV-2 Infection in Patients with Autoimmune Rheumatic Diseases in Qatar: A Cohort Matched Study
Qatar Medical Journal 2022, 24 (2022); https://doi.org/10.5339/qmj.2022.24
/content/journals/10.5339/qmj.2022.24
/content/journals/10.5339/qmj.2022.24
Loading

Data & Media loading...

Keyword(s): Autoimmune rheumatic disease, Disease-modifying antirheumatic drugs, Poor prognostic factors, Severe acute respiratory syndrome coronavirus 2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error